Trends in Pharmacological Sciences
The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins
Section snippets
BCRP, a pharmacologically important ABC multidrug transporter
Multidrug transporters of the ATP binding cassette (ABC) family are membrane-spanning efflux pumps that can actively extrude a wide range of structurally different drugs, carcinogens and other xenotoxins across the plasma membrane of cells. This ATP-dependent efflux can occur against steep concentration gradients. In this way, ABC transporters can confer multidrug resistance to tumour cells. Moreover, several of these transporters have prominent physiological roles in the body because they
Biochemical properties and substrate specificity of BCRP
BCRP was named breast cancer resistance protein merely because it was first cloned from a multidrug-resistant breast cancer cell line. However, there is no indication that BCRP is specific or even typical for breast cancer cells because many of these cells lack substantial BCRP expression. By its localization in the plasma membrane BCRP can actively extrude a wide variety of drugs, such as the anticancer drugs mitoxantrone, topotecan and methotrexate, from cells, thus conferring resistance to
BCRP limits the oral availability of drugs and mediates their excretion
Both in humans and in mice, BCRP/BCRP1 is situated strategically in the apical membrane of epithelial cells of the small and large intestine and in the bile canalicular membrane of hepatocytes (Figure 2). This enables BCRP/BCRP1 to limit the oral availability of its substrates by mediating rapid hepatobiliary and direct intestinal excretion, and probably also by reducing net uptake from the gut lumen. This is supported by several studies. For example, because of the lack of BCRP1, the plasma
BCRP/BCRP1 protects crucial tissues from xenotoxins
BCRP and BCRP1 are abundant in the luminal membrane of endothelial cells of blood capillaries in the brain and in placental syncytiotrophoblasts, where they can limit the penetration of xenotoxins across the blood–brain and maternal–foetal barriers, respectively (Figure 2). The foetal penetration of topotecan, for example, is twofold increased in mice when placental BCRP1 is absent [7]. In the brain of BCRP1-deficient mice, compared with wild-type mice, a twofold higher penetration of the
BCRP/BCRP1 protects organisms from natural dietary toxins
A striking illustration of the role of BCRP1 in protection from natural xenotoxins has been observed in BCRP1-deficient mice. These mice displayed a highly increased susceptibility to phototoxicity compared with wild-type mice, resulting in severe ear lesions [7]. This phenotype was caused by the dietary phototoxin ‘pheophorbide a’, a chlorophyll-breakdown product that can be found in several animal feeds and sometimes in human food supplements. Whereas wild-type mice are protected efficiently
BCRP/BCRP1 expression in stem cells and progenitor cells
In stem cell research, the capacity to efflux the fluorescent dye Hoechst 33342 is an important marker for the isolation of haematopoietic stem cells from bone marrow (Figure 3) [14]. This efflux capacity of Hoechst 33342 by stem cells, resulting in a side population (SP) in fluorescence-activated cell sorting (FACS) plots with a characteristic amount and ratio of ‘blue’ versus ‘red’ fluorescence, is conferred by BCRP1 [15]. BCRP1 is expressed at substantial levels in primitive murine
Implications for BCRP inhibitor use in cancer chemotherapy
The protective role of BCRP/BCRP1 in haematopoietic and possibly other tissue stem cells might complicate the application of efficacious BCRP inhibitors to improve the chemotherapy response of BCRP-expressing tumours. The expression of BCRP in human leukaemias and solid tumours has been demonstrated in several studies, some of which can associate BCRP expression with relapse or refractory disease, or as a prognostic factor for overall survival 5, 25. To specifically enhance the availability of
Drug and xenotoxin secretion into milk
Many unique advantages of human breast milk for providing infant nutrition support the major trend in the developed world to return to breast-feeding. However, concerns have been raised over maternal drug transfer to the suckling infant [26]. Although breast-feeding women can take several drugs safely, reports of toxicity in breast-fed infants as a result of pharmacologically significant levels of drug exposure exist [27]. Importantly, environmental and dietary toxins and carcinogens, in
BCRP secretes drugs and xenotoxins into milk
BCRP/BCRP1 was identified recently as a major factor in the active secretion of xenotoxins into milk [33]. Whereas BCRP1 is not expressed in mammary epithelial tissue of virgin mice, it is strongly induced during late pregnancy and particularly during lactation. BCRP1 is located primarily in the apical membrane of alveolar epithelial cells (i.e. at the main site of milk production) but not in main ducts (Figure 2) [33]. To assess the functional role of BCRP1 in the mammary gland, the milk
BCRP1-mediated secretion of carcinogens into milk
In addition to PhIP, two other heterocyclic amine dietary carcinogens, IQ and Trp-P-1, are secreted into milk by BCRP1, albeit not as efficiently as PhIP. The same applies to the potent human hepatocarcinogen aflatoxin B1 (Table 1) [24]. Aflatoxin B1 is one of the most potent mycotoxins known to man and an important risk factor for the development of hepatocellular carcinoma in humans 36, 37. This BCRP1-mediated active transfer of xenotoxins can be a serious health threat: for example, milk
Pharmacological implications of BCRP expression in the mammary gland
The expression of BCRP in the mammary gland during lactation is conserved in cows and humans [33]. Given the similarity in substrates transported by mouse and human BCRP [4], the clinical significance of BCRP activity in the lactating mammary gland is evident: drugs and drug metabolites that are good BCRP substrates have a high chance of being concentrated into milk and should thus be examined carefully for the risk of dangerously increased exposure levels in infants or dairy consumers. The
Endogenous role of BCRP1 expression in the mammary gland?
The physiological function of BCRP in secreting xenotoxins into milk is puzzling because this activity potentially exposes the vulnerable suckling infant to a range of xenotoxins. Everywhere else in the body BCRP appears to have a xenotoxin-protective role, including protection of the foetus before birth. One option is that BCRP might be used to secrete a variety of nutrients into milk, offsetting the risk of xenotoxin contamination. However, several obvious candidate nutrients that are known
Concluding remarks
The aforementioned studies have revealed several new and important pharmacological and toxicological functions of BCRP. The activity of BCRP in haematopoietic and other stem and progenitor cells might affect the sensitivity of patients to dose-limiting side-effects of cancer chemotherapy and the chemotherapy response of tumours. BCRP activity can vary extensively because of: (i) known genetic polymorphisms and gender 44, 45, 46, 47; (ii) intentional or coincidental use of drugs that inhibit
Acknowledgements
We thank J.W. Jonker and the audiovisual centre NKI for kindly providing Figure 1, Figure 2, respectively. We thank M. Vlaming, E. van de Steeg and J.H. Beijnen for useful comments on the text. This work was supported in part by grants from the Dutch Cancer Society and NWO/STW.
References (49)
Importance of P-glycoprotein at blood-tissue barriers
Trends Pharmacol. Sci.
(2004)- et al.
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
Adv. Drug Deliv. Rev.
(2003) The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature hematopoietic progenitors
Blood
(2002)Hepatic oval cells have the side population phenotype defined by expression of ATP-binding cassette transporter ABCG2/BCRP1
Am. J. Pathol.
(2003)Nestin-positive progenitor cells derived from adult human pancreatic islets of Langerhans contain side population (SP) cells defined by expression of the ABCG2 (BCRP1) ATP-binding cassette transporter
Biochem. Biophys. Res. Commun.
(2002)Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart
Dev. Biol.
(2004)Drug excretion into breast milk-overview
Adv. Drug Deliv. Rev.
(2003)Acyclovir concentrations in human breast milk after valaciclovir administration
Am. J. Obstet. Gynecol.
(2002)- Breedveld, P. et al. (2006) Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS...
- et al.
Mammalian ABC transporters in health and disease
Annu. Rev. Biochem.
(2002)
Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)
Oncogene
Tumour stem cells and drug resistance
Nat. Rev. Cancer
The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria
Proc. Natl. Acad. Sci. U. S. A.
Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan
J. Natl. Cancer Inst.
Increased oral availability of topotecan in combination with the breast cancer resistance protein and p-glycoprotein inhibitor GF120918
J. Clin. Oncol.
Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl)benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice
Drug Metab. Dispos.
The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of BCRP and P-gp inhibitors to enable the brain penetration of imatinib in patients
Cancer Res.
The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine
Cancer Res.
Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazole(4,5-b)pyridine, and transport of cimetidine
J. Pharmacol. Exp. Ther.
Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo
J. Exp. Med.
The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype
Nat. Med.
Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo
Proc. Natl. Acad. Sci. U. S. A.
‘Side population’ cells in adult mouse testis express Bcrp1 gene and are enriched in spermatogonia and germinal stem cells
Development
Cited by (175)
Ivermectin inhibits ovine ABCG2-mediated in vitro transport of meloxicam and reduces its secretion into milk in sheep
2022, Research in Veterinary ScienceTargeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators
2022, European Journal of Medicinal ChemistryMechanisms and genetics of drug transport
2021, Atkinson's Principles of Clinical PharmacologyAbcg2 transporter affects plasma, milk and tissue levels of meloxicam
2020, Biochemical PharmacologyAssociation between ABCB1, ABCG2 carrier protein and COX-2 enzyme gene polymorphisms and breast cancer risk in a Turkish population
2020, Saudi Pharmaceutical JournalThe occurrence of mycotoxins in breast milk, fruit products and cereal-based infant formula: A review
2019, Trends in Food Science and Technology